Vaxcyte COO Wassil Jim sold 2,715 shares in two transactions priced from $59.52 to $61.16 per share. The reported post-transaction holdings were 145,435 shares after the sales and 146,769 shares after a separate forfeiture of 5,459 shares, giving investors two ownership figures to track.
Key Highlights
- Wassil Jim forfeited 5,459 shares at $60.36 per share on September 8.
- Jim’s reported holding after the sales was 145,435 shares.
- The forfeiture represented about 3.6% of Jim’s prior shareholding.
Vaxcyte, Inc. (NASDAQ: PCVX) executive Wassil Jim sold 2,715 shares across two transactions priced from $59.52 to $61.16 per share. Jim serves as executive vice president, chief scientific officer and chief operating officer.
Transaction Details Include September Sale Dates The
sales took place between September 4 and September 9, with both transactions carrying code S. The transaction record also shows Jim forfeited 5,459 shares at $60.36 per share on September 8 under code F. Following the sales, Jim’s reported ownership stood at 145,435 shares. After the forfeiture, his reported holding was 146,769 shares.
Forfeiture Represented 3.6%
of Prior Holding The forfeiture represented about 3.6% of Jim’s prior shares holding in Vaxcyte, Inc. Transaction code S identifies the reported sales, while code F identifies the forfeiture. The filing reports separate ownership figures after the sales and forfeiture. The filing states that the 3.6% figure applies to the forfeiture.
FAQs
Q: What shares did Wassil Jim sell in Vaxcyte?
A: Wassil Jim sold 2,715 Vaxcyte shares across two transactions. The sale prices ranged from $59.52 to $61.16 per share between September 4 and September 9.
Q: What happened to Wassil Jim’s Vaxcyte holdings?
A: Jim’s reported holding was 145,435 shares after the sales. The filing separately reports a forfeiture on September 8, after which ownership was 146,769 shares. These figures are listed after the respective transaction types.
Q: How large was the Vaxcyte share forfeiture?
A: Jim forfeited 5,459 Vaxcyte shares at $60.36 per share on September 8. The transaction represented about 3.6% of his prior shareholding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.